82240-03-7

Upstream product

• 16715-88-1 4-(4-hydroxyphenyl)cyclohexanol 
• 92-88-6 4,4'-Dihydroxybiphenyl 
• 105640-07-1 4-(4-hydroxyphenyl)cyclohexan-1-one 
• 100-39-0 benzyl bromide 
• 100-44-7 benzyl chloride 

Downstream Products

• 102162-14-1 (1r,4r)-4-(4-(benzyloxy)phenyl)cyclohexan-1-ol 
• 82240-04-8 α-<1-idrossi-4-(4-benzilossifenil)cicloesil>butirrato d'etile 
• 860616-71-3 6-(4-benzyloxy-phenyl)-spiro[2.5]octane 
• 860616-51-9 6-[4-(3-bromo-propoxy)-3-chloro-phenyl]-spiro[2.5]octane 
• 82205-94-5 acido α-<1-idrossi-4-(4-idrossifenil)cicloesil>butirrico 
• 82240-05-9 acido α-<1-idrossi-4-(4-benzilossifenil)cicloesil>butirrico 
• 103212-34-6 trans-1-(4-benzyloxy-phenyl)-4-(toluene-4-sulfonyloxy)-cyclohexane 
• 865458-75-9 1-[4-(4-benzyloxyphenyl)-cyclohex-1-enyl]-pyrrolidine 
• 259664-11-4 trans 4-(4-benzyloxy-phenyl)-cyclohexyl-amine 
• 1402465-91-1 methyl 2-(4-(4-(benzyloxy)phenyl)cyclohexylidene)acetate 
• 1402465-92-2 methyl 6-(4-(benzyloxy)phenyl)spiro[2.5]octane-1-carboxylate 
• 1402465-93-3 methyl 6-(4-hydroxyphenyl)spiro[2.5]octane-1-carboxylate 

Relevant academic research and scientific papers

Metal-Free C-O Bond Functionalization: Catalytic Intramolecular and Intermolecular Benzylation of Arenes

A catalytic, metal-free intramolecular rearrangement of benzyl phenyl ethers using nitrosonium salt as a catalyst is described. The optimized reaction conditions enabled a catalytic and metal-free Friedel-Crafts alkylation reaction with benzylic alcohols, producing water as the stoichiometric byproduct. A comprehensive scope (>50 examples) for both approaches and application in drug synthesis were demonstrated. Mechanistic studies suggest a Lewis acid-based mechanism for the metal-free Friedel-Crafts reaction.

Method for synthesizing 4-(4-hydroxyphenyl) cyclohexanone

The invention belongs to the technical field of electronic material intermediate, and discloses a method for synthesizing 4-(4-hydroxyphenyl) cyclohexanone. The method comprises the following steps: reducing 4,4'-diphenol with Al-Ni to prepare 4-(4-cyclohexanamide)-phenol; then preparing 4-(4-benzyloxy-benzene) cyclohexanol with benzyl chloride protection; oxidizing with chromium trioxide to obtain 4-(4-benzyloxy-benzene) cyclohexanone; and finally hydrogenating with 5% Pd/C to obtain 4-(4-hydroxyphenyl) cyclohexanone having a molecular formula of C12H14O2. The 4-(4-hydroxyphenyl) cyclohexanone prepared by the method is an electronic material and medicinal intermediate; and the synthesizing method has the advantages of reasonable process design, high yield and short production cycle, is economical and feasible, and easily realizes industrial production.

Development of Phenyl Cyclohexylcarboxamides as a Novel Class of Hsp90 C-terminal Inhibitors

Inhibition of the heat shock protein 90 (Hsp90) C-terminus represents a promising therapeutic strategy for the treatment of cancer. Novobiocin, a coumarin antibiotic, was the first Hsp90 C-terminal inhibitor identified, however, it manifested poor anti-proliferative activity (SKBr3, IC50≈700 μm). Subsequent structure–activity relationship (SAR) studies on novobiocin led to development of several analogues that exhibited improved anti-proliferative activity against several cancer cell lines. Recent studies demonstrate that the biphenyl core could be used in lieu of the coumarin ring system, which resulted in more efficacious analogues. In continuation of previous efforts, the work described herein has identified the phenyl cyclohexyl core as a novel scaffold for Hsp90 C-terminal inhibition. Structure–activity relationship (SAR) studies on this scaffold led to the development of compounds that manifest mid-nanomolar activity against SKBr3 and MCF-7 breast cancer cell lines through Hsp90 inhibition.

COMPOSITIONS AND METHODS FOR MODULATING LPA RECEPTORS

The present invention relates to compounds of Formula (1), or pharmaceutically acceptable salts thereof and their pharmaceutical compositions, wherein variables are as defined herein, which are useful as modulators of the activity of lysophosphatidic acid (LPA).

INHIBITORS OF DIACYLGLYCEROL O-ACYLOTRANSFERASE TYPE 1 ENZYME

Compounds of formula (I), or a pharmaceutically acceptable salt, prodrug, salt of a prodrug, or a combination thereof. Pharmaceutical compositions of formula (I) and related methods for treating or preventing metabolic diseases or conditions.

Discovery of novel and orally active NR2B-selective N-methyl-d-aspartate (NMDA) antagonists, pyridinol derivatives with reduced HERG binding affinity

Novel NR2B antagonists with an amide tether were found by an approach to avoid pharmacophoric similarity to dofetilide. Structure-activity relationship investigation led to N-[cis-4-hydroxy-4-(5-hydroxypyridin-2-yl)cyclohexyl]-3-henylpropanamide 14e as an